8/107 sources · 6 publishersUpdated Nov 16, 23:01 UTC
Merck KGaA agrees to buy Rapid Micro Biosystems in cash deal
On Nov. 16, 2026, Merck KGaA agreed to purchase Rapid Micro Biosystems in a cash transaction valuing each Rapid share at $0.75. The planned tender offer would bring Rapid’s Growth Direct automated microbial quality-control platform into Merck’s Life Science business. Completion is targeted for December 2026, subject to the tender offer and other closing requirements.
Why it matters
Rapid shareholders have a stated cash consideration, but payment depends on the tender offer and other closing conditions. Merck would add Rapid’s automated microbial-testing platform to its pharmaceutical quality-control portfolio if the transaction closes.
Key facts
- 1Merck KGaA agreed to acquire all outstanding Rapid Micro Biosystems shares for $0.75 each in an all-cash transaction. finance.yahoo.com
- 2The transaction is expected to close in December 2026, subject to the tender offer’s minimum condition and other customary closing requirements. finance.yahoo.com
- 3The tender condition requires valid tenders representing at least a majority of Rapid’s outstanding voting shares, including shares issuable upon exercise of pre-funded warrants. globenewswire.com
- 4Rapid’s Growth Direct platform automates microbial quality-control testing, including incubation, imaging and colony counting. globenewswire.com
- 5The tender offer had not commenced when Merck announced the agreement. globenewswire.com
Open questions
- Material 7 says Rapid’s board approved the transaction, but the supplied company materials do not state that approval.
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.